Corbus Pharma Begins First-In-Human Dosing of CRB-601 for Advanced Solid Tumors

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), an oncology and obesity-focused company, has initiated the Phase 1 clinical study of CRB-601 for the treatment of advanced solid tumors. The first patient has been dosed in this study, which is identified under the clinical trial number NCT06603844.

CRB-601 is an anti-αvβ8 monoclonal antibody intended to inhibit the activation of latent TGFβ within the tumor micro-environment. This inhibition can play a crucial role in overcoming tumor immune exclusion, thereby enhancing the effectiveness of immune checkpoint inhibitors, as shown in preclinical studies.

Dr. Dominic Smethurst, Chief Medical Officer of Corbus, expressed that CRB-601’s approach to modulating TGFβ signaling is intriguing and the dose escalation study could provide significant insights. There is a potential for the immune system to be mobilized and for tumors to respond positively.

Dr. Jeffrey M. Clarke, an Associate Professor of Medicine, Associate Director of Thoracic Oncology Clinical Research Program at Duke Cancer Institute, and principal investigator in the CRB-601 study, emphasized that dosing CRB-601 in a clinical trial is a significant milestone. This advancement brings the scientific community closer to understanding the clinical potential of CRB-601 and represents progress in the field of immunotherapy.

Corbus Pharmaceuticals Holdings, Inc., based in Norwood, Massachusetts, aims to address serious illnesses by leveraging innovative scientific methods related to well-understood biological pathways. The company's pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells to deliver a cytotoxic payload, and CRB-913, a CB1 inverse agonist designed to treat obesity.

Corbus remains dedicated to advancing its portfolio and contributing to the fight against cancer and obesity through rigorous scientific research and clinical trials.